In light of persistent vasculitis activity, manifested by pulmonary infiltrates and elevated MPO-ANCA titers, and refractory anemia unresponsive to prior therapy, RTX (500 mg every two weeks) was initiated after ruling out contraindications. The gene discussed is MPO; the disease is anemia.